In the present study, we found that AGL9 administration substantially decreased adiponectin levels and rescued the NAFLD phenotype, suggesting its potential as a treatment strategy for lipid-metabolism disorders. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.